↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Mobia Medical$MOBI · filed: 🫧 Edgar looked up MOBIA MEDICALCheck ▾Close ▴
What Mobia Medical filed
🫧 Edgar looked up MOBIA MEDICAL, INC. ($MOBI). Last filing: 10-Q, 2026-11-05. 5 event filings (8-K) in the past twelve months. Every figure links to the filing it came from on Mobia Medical’s card.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Mobia brings neurotech exposure to public markets, but single-product risk and pending reimbursement cuts demand pricing discipline at IPO.
$150 million
initial public offering with pricing expected within 72 hours
87%
of the
$8.2 billion
global market
$42 million
in trailing-twelve-month revenue
Mobia Medical filed terms for a $150 million initial public offering with pricing expected within 72 hours, entering a neuromodulation segment where three established manufacturers control 87% of the $8.2 billion global market. The San Diego–based company makes peripheral nerve stimulation devices that treat chronic pain without opioids, competing directly against Abbott's Proclaim and Medtronic's Intellis platforms.
The prospectus disclosed $42 million in trailing-twelve-month revenue, up 68% year-over-year, with gross margins at 71%—five points below Abbott's neuro division but seven points above the median for pre-profitable device makers. Mobia burned $38 million in cash over the same period. The company holds FDA clearance for its primary device but lacks the European CE Mark, which represents $2.1 billion in addressable market it cannot yet access. Lead underwriters are Jefferies and Piper Sandler.
The timing matters because healthcare IPOs raised $4.1 billion in the first quarter, the strongest start since 2021, but device makers specifically face tightening reimbursement schedules. CMS finalized a 3.1% cut to outpatient facility payments for neurostimulators effective July 1, which applies to all manufacturers but disproportionately pressures those without diversified revenue streams. Mobia derives 91% of revenue from a single product line, compared to 34% for Abbott's neuromodulation unit. Public investors will also compare Mobia's valuation to Nevro, which trades at 2.8x trailing revenue after cutting guidance twice in eight months.
The IPO gives Mobia capital to pursue the CE Mark and fund a pivotal trial for spinal cord stimulation, the larger adjacent market worth $3.4 billion annually. The trial requires 340 patients and 18 months of follow-up data, meaning commercialization would not occur before mid-2027. Without that expansion, Mobia competes in peripheral nerve stimulation—a $900 million niche where reimbursement remains inconsistent and physician adoption hinges on sales force density. Abbott employs 280 neuromodulation reps in the U.S. alone; Mobia disclosed a team of 47.
Allocators should watch the final share price against the bookbuild, expected to close Tuesday evening. A discount to the midpoint would signal institutional caution on single-product exposure and the European regulatory path. The post-IPO quiet period expires in 25 days, when analysts will publish models. CMS releases updated fee schedules for 2026 in November, which will clarify whether the reimbursement cuts are structural or a one-time adjustment. Mobia's lock-up expires 180 days after pricing, which puts insider selling in late Q4.
Branded by POPS4 · proof in 60 seconds
For the principal
Consider allocation only below midpoint; single-product risk and CMS cuts warrant a structural discount to diversified neuro peers like Abbott.
For the operator
Watch the bookbuild close Tuesday and compare pricing to Nevro's 2.8x revenue multiple before committing capital to this name.
For the house
Huang Goodman passes primary; we enter if trading opens 12% below price and gross margins expand in the first earnings print.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.